Compare Salesforce Inc (CRM) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Tempus AI — how do they compare? Salesforce Inc trades at $168.99 (market cap $137.23B), while Tempus AI trades at $58.03 (market cap $10.54B). The key difference: Salesforce Inc is far larger — about 13× Tempus AI's market cap, and Salesforce Inc pays a 1.05% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| CRM | TEM | |
|---|---|---|
Market Cap | $137.23B | $10.54B |
Sector | Technology | Broad Market / Factor |
52-Week High | $270.25 | $103.25 |
52-Week Low | $150.12 | $42.37 |
Enterprise Value | $167.28B | $11.21B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.09, down slightly by 0.08% on the day, amid a neutral technical signal and recent sector-wide pressure on software stocks. The company demonstrates strong fundamentals with consistent earnings beats, robust profitability margins, and solid revenue growth, though its stock has faced a significant year-to-date decline. Recent news highlights AI-driven growth potential but also reflects market concerns over competitive threats from advancing AI technologies.
The outlook remains cautiously optimistic given strong analyst support, a consensus price target of $235.90, and the company's strategic focus on AI monetization. Key risks include heightened competition in the SaaS space, macroeconomic volatility impacting tech spending, and execution challenges in sustaining high growth rates. Current valuation metrics present a potential entry point for long-term investors despite near-term headwinds.
Tempus AI (TEM) trades at $55.93, down 3.95% on the day, with strong analyst support (61.5% buy ratings) and a $69.20 consensus price target. The stock shows bullish technical signals with support at $55 and resistance at $58, while fundamentals reveal robust revenue growth ($1.27B in 2025) but significant losses (-$245M net income). Recent news highlights the company's expanding AI healthcare data platform and FDA approvals driving investor optimism despite ongoing profitability challenges.
TEM presents a high-risk, high-reward opportunity with Wall Street bullish on its unique healthcare data moat and AI capabilities. The primary investment thesis centers on the company's positioning to dominate precision medicine, though shareholders face substantial execution risk amid persistent losses and negative cash flow from operations. Near-term catalysts include Q2 2026 earnings on July 30 and continued expansion of high-margin data services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
